References

Wearing-off scales in parkinson’s disease: critique and recommendations

10.1002/mds.23875 · 2011 · External reference

Medical management and prevention of motor complications in Parkinson’s disease

10.1007/s13311-020-00889-4 · 2020 · External reference

Nomograms in oncology: more than meets the eye

10.1016/s1470-2045(14)71116-7 · 2015 · External reference

The role of dopaminergic medication and specific pathway alterations in idiopathic and PRKN/PINK1 -mediated Parkinson’s disease

10.1126/sciadv.adp7063 · 2025 · External reference

Mitophagy in neurons: mechanisms regulating mitochondrial turnover and neuronal homeostasis

10.1016/j.jmb.2025.169161 · 2025 · External reference

Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease

10.1126/science.aam9080 · 2017 · External reference

Mitochondrial unfolded protein response (UPRmt) as novel therapeutic targets for neurological disorders

10.1177/0271678x251341293 · 2026 · External reference

Mitochondrial quality control via mitochondrial unfolded protein response (mtUPR) in ageing and neurodegenerative diseases

10.3390/biom13121789 · 2023 · External reference

Parkin and mitochondrial signalling

10.1016/j.cellsig.2023.110631 · 2023 · External reference

Fluid and biopsy based biomarkers in Parkinson’s disease

10.1007/s13311-023-01379-z · 2023 · External reference

A multilayered stress-response circuit: the mammalian mitochondrial UPR

10.1111/febs.70607 · 2026 · External reference

Oxidative stress and regulated cell death in Parkinson’s disease

10.1016/j.arr.2021.101263 · 2021 · External reference

Unresolved reference

1994 · External reference

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort

10.1038/s41531-018-0069-x · 2018 · External reference

Plasma-derived phosphoglycerate mutase 5 as a biomarker for Parkinson’s disease

10.3389/fnagi.2022.1022274 · 2022 · External reference

Olfactory dysfunction in Parkinsonism caused by PINK1 mutations

10.1002/mds.22816 · 2009 · External reference

The transcription factor ATF5 mediates a mammalian mitochondrial UPR

10.1016/j.cub.2016.06.002 · 2016 · External reference

An explainable ensemble machine learning model using baseline blood transcriptomics to predict Parkinson’s disease motor progression

10.3389/fdgth.2026.1774436 · 2026 · External reference

“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician

10.1016/0022-3956(75)90026-6 · 1975 · External reference

Motor complications of dopaminergic medications in Parkinson’s disease

10.1055/s-0037-1602423 · 2017 · External reference

Activation mechanism of PINK1

10.1038/s41586-021-04340-2 · 2022 · External reference

Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results

10.1002/mds.22340 · 2008 · External reference

Peripheral-central immune crosstalk in Parkinson’s disease and its association with clinical severity

10.1016/j.bbi.2025.04.028 · 2025 · External reference

The assessment of anxiety states by rating

10.1111/j.2044-8341.1959.tb00467.x · 1959 · External reference

A rating scale for depression

10.1136/jnnp.23.1.56 · 1960 · External reference

Deficiency of parkin causes neurodegeneration and accumulation of pathological α-synuclein in monkey models

10.1172/jci179633 · 2024 · External reference

Physiological and pathological roles of PGAM5: an update and future trend

10.1016/j.isci.2024.111539 · 2025 · External reference

Parkin characteristics and blood biomarkers of Parkinson’s disease in WPBLC study

2025 · External reference

Parkinsonism: onset, progression and mortality

10.1212/wnl.17.5.427 · 1967 · External reference

UPRmt activation protects against MPP+-induced toxicity in a cell culture model of Parkinson’s disease

10.1016/j.bbrc.2021.06.079 · 2021 · External reference

Current knowledge on the background, pathophysiology and treatment of levodopa-induced dyskinesia-literature review

10.3390/jcm10194377 · 2021 · External reference

Adjusting batch effects in microarray expression data using empirical Bayes methods

10.1093/biostatistics/kxj037 · 2007 · External reference

Parkinson’s disease

10.1016/s0140-6736(14)61393-3 · 2015 · External reference

Genotype-phenotype relations for the Parkinson’s disease genes parkin, PINK1, DJ1: MDSGene systematic review

10.1002/mds.27352 · 2018 · External reference

Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function

10.1001/jama.1963.03060120024016 · 1963 · External reference

The sva package for removing batch effects and other unwanted variation in high-throughput experiments

10.1093/bioinformatics/bts034 · 2012 · External reference

Validation of a new REM sleep behavior disorder questionnaire (RBDQ-HK)

10.1016/j.sleep.2009.06.008 · 2010 · External reference

Neuronal autophagy and mitophagy in Parkinson’s disease

10.1016/j.mam.2021.100972 · 2021 · External reference

UPRmt regulation and output: a stress response mediated by mitochondrial-nuclear communication

10.1038/cr.2018.16 · 2018 · External reference

The role of PINK1–parkin in mitochondrial quality control

10.1038/s41556-024-01513-9 · 2024 · External reference

Ubiquitin signaling in PINK1/parkin-dependent mitophagy

10.1093/jb/mvaf079 · 2026 · External reference

Gender is the main predictor of wearing-off and dyskinesia in levodopa-naïve patients with Parkinson’s disease

10.1002/mdc3.70143 · 2025 · External reference

MDS clinical diagnostic criteria for Parkinson’s disease

10.1002/mds.26424 · 2015 · External reference

A blood-based marker of mitochondrial DNA damage in Parkinson’s disease

10.1126/scitranslmed.abo1557 · 2023 · External reference

Identification of mitophagy-associated proteins profile as potential plasma biomarkers of idiopathic Parkinson’s disease

10.1111/cns.14532 · 2024 · External reference

PINK1/PARKIN signalling in neurodegeneration and neuroinflammation

10.1186/s40478-020-01062-w · 2020 · External reference

Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis

10.1198/jasa.2003.s263 · 2003 · External reference

Mechanism of PINK1 activation by autophosphorylation and insights into assembly on the TOM complex

10.1016/j.molcel.2021.11.012 · 2022 · External reference

Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression

10.1007/s00702-025-02893-4 · 2025 · External reference

A MAPK/c-jun-mediated switch regulates the initial adaptive and cell death responses to mitochondrial damage in a neuronal cell model

10.1016/j.biocel.2018.09.008 · 2018 · External reference

Striatal synaptic dysfunction in dystonia and levodopa-induced dyskinesia

10.1016/j.nbd.2022.105650 · 2022 · External reference

Mitochondrial quality control as a key determinant of cell survival

10.1016/j.bbamcr.2018.12.012 · 2019 · External reference

Parkinson’s disease-linked parkin mutation disrupts recycling of synaptic vesicles in human dopaminergic neurons

10.1016/j.neuron.2023.08.018 · 2023 · External reference

Regression shrinkage and selection via the lasso

10.1111/j.2517-6161.1996.tb02080.x · 1996 · External reference

Systematic review of levodopa dose equivalency reporting in Parkinson’s disease

10.1002/mds.23429 · 2010 · External reference

RNA sequencing of olfactory bulb in Parkinson’s disease reveals gene alterations associated with olfactory dysfunction

10.1016/j.nbd.2024.106514 · 2024 · External reference

IFN-β rescues neurodegeneration by regulating mitochondrial fission via STAT5, PGAM5, and Drp1

10.15252/embj.2020106868 · 2021 · External reference

Mitochondrial DNA heteroplasmy distinguishes disease manifestation in PINK1/PRKN-linked Parkinson’s disease

10.1093/brain/awac464 · 2023 · External reference

Decision curve analysis: a novel method for evaluating prediction models

10.1177/0272989x06295361 · 2006 · External reference

PLS-regression: a basic tool of chemometrics

10.1016/s0169-7439(01)00155-1 · 2001 · External reference

Global, regional and national burden of Parkinson’s disease, 1990–2021: update from the GBD 2021 study

10.1016/j.jns.2025.125703 · 2026 · External reference

The heterogeneity of Parkinson’s disease: clinical and prognostic implications

10.1212/wnl.35.4.522 · 1985 · External reference

Mitochondria at the crossroads: quality control mechanisms in neuronal senescence and neurodegeneration

10.1016/j.nbd.2025.106862 · 2025 · External reference

NAD+-boosters improve mitochondria quality control in Parkinson’s disease models via mitochondrial UPR

2025 · External reference

Temporal trends in the prevalence of Parkinson’s disease from 1980 to 2023: a systematic review and meta-analysis

10.1016/s2666-7568(24)00094-1 · 2024 · External reference